tizanidine has been researched along with Myelopathy in 6 studies
tizanidine: RN given refers to parent cpd; structure
tizanidine : 2,1,3-Benzothiadiazole substituted at C-4 by a Delta(1)-imidazolin-2-ylamino group and at C-4 by a chloro group. It is an agonist at alpha2-adrenergic receptor sites.
| Excerpt | Relevance | Reference |
|---|---|---|
| " Wide interpatient variability in the effective plasma concentrations of tizanidine means that the optimal dosage must be titrated over 2 to 4 weeks for each patient (dosages of 2 to 36 mg/day have been used in clinical trials)." | 2.40 | Tizanidine. A review of its pharmacology, clinical efficacy and tolerability in the management of spasticity associated with cerebral and spinal disorders. ( Bryson, HM; Wagstaff, AJ, 1997) |
| "With the introduction of the antispasticity agent, tizanidine hydrochloride (Zanaflex), physicians have requested information about the optimal way to switch appropriate patients from baclofen to tizanidine." | 2.40 | An approach to switching patients from baclofen to tizanidine. ( Brenner, R; Hyman, N; Knobler, R; O'Brien, M; Stephan, T, 1998) |
| " It has low oral bioavailability and short halflife." | 1.56 | Optimization of Microemulgel for Tizanidine Hydrochloride. ( Brahmane, S; Chabukswar, A; Jagdale, S, 2020) |
| " Treatment was started with DS 103-282 at a mean dosage of 7." | 1.26 | The spasmolytic properties of 5-chloro-4-(2-imidazolin-2-yl-amino)-2, 1,3-benzothiadiazole hydrochloride (DS 103-282): a pilot study. ( Lakke, JP; Sie, OG, 1980) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (16.67) | 18.7374 |
| 1990's | 2 (33.33) | 18.2507 |
| 2000's | 1 (16.67) | 29.6817 |
| 2010's | 1 (16.67) | 24.3611 |
| 2020's | 1 (16.67) | 2.80 |
| Authors | Studies |
|---|---|
| Jagdale, S | 1 |
| Brahmane, S | 1 |
| Chabukswar, A | 1 |
| Nguyen, H | 2 |
| Le, C | 1 |
| Ray, BK | 1 |
| Guha, G | 1 |
| Misra, AK | 1 |
| Das, SK | 1 |
| Sie, OG | 1 |
| Lakke, JP | 1 |
| Wagstaff, AJ | 1 |
| Bryson, HM | 1 |
| Brenner, R | 1 |
| Hyman, N | 1 |
| Knobler, R | 1 |
| O'Brien, M | 1 |
| Stephan, T | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| The Clinical Effect and Sonographic Findings of Kinesiotaping Combined With Therapeutic Exercise in Upper Extremity Spasticity and Function in Subacute Stroke Patients[NCT03024190] | 36 participants (Actual) | Interventional | 2017-01-31 | Completed | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
2 reviews available for tizanidine and Myelopathy
| Article | Year |
|---|---|
Tizanidine. A review of its pharmacology, clinical efficacy and tolerability in the management of spasticity associated with cerebral and spinal disorders.
Topics: Adrenergic alpha-Agonists; Animals; Brain Diseases; Clinical Trials as Topic; Clonidine; Humans; Mus | 1997 |
An approach to switching patients from baclofen to tizanidine.
Topics: Baclofen; Clinical Competence; Clonidine; Humans; Multiple Sclerosis; Muscle Relaxants, Central; Mus | 1998 |
4 other studies available for tizanidine and Myelopathy
| Article | Year |
|---|---|
Optimization of Microemulgel for Tizanidine Hydrochloride.
Topics: Administration, Cutaneous; Animals; Biological Availability; Cells, Cultured; Chickens; Clonidine; D | 2020 |
Cervical myelopathy from spinal sarcoidosis as the unexpected initial presentation for systemic sarcoidosis.
Topics: Adult; Cervical Vertebrae; Clonidine; Contrast Media; Gadolinium DTPA; Glucocorticoids; Humans; Hype | 2010 |
Involuntary jerking of lower half of the body (spinal myoclonus).
Topics: Baclofen; Clonazepam; Clonidine; Diagnosis, Differential; Humans; Lower Extremity; Middle Aged; Myoc | 2005 |
The spasmolytic properties of 5-chloro-4-(2-imidazolin-2-yl-amino)-2, 1,3-benzothiadiazole hydrochloride (DS 103-282): a pilot study.
Topics: Adult; Aged; Blood Pressure; Clonidine; Female; Humans; Male; Middle Aged; Parasympatholytics; Pilot | 1980 |